Penetrium Bioscience페니트리움바이오
187660 · KOSDAQ · ₩187660 · 페니트리움바이오
₩6,100▼ ₩70 (1.13%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 6.1% | 0.4% | 1.0% | 23.3% | 29.4% | 51.9% |
| Operating margin | −80.3% | −79.5% | −163.5% | −13.9% | 3.5% | 17.3% |
| Net margin | −196.1% | −159.9% | −228.0% | −27.6% | 7.7% | 15.3% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −10.0% | −4.8% | −29.3% | −7.3% | +6.5% | — |
| Operating income growth | +9.2% | +53.7% | −733.7% | −470.0% | −78.6% | — |
| Net income growth | −10.3% | +33.3% | −484.8% | −432.2% | −46.5% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −73.6% | −106.4% | −126.5% | −12.3% | 3.4% | 6.2% |
| Return on assets | −48.9% | −48.6% | −61.0% | −8.3% | 2.7% | 5.5% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 48.8% | 52.3% | 344.8% | 54.9% | 43.0% | 12.3% |
| Net debt to equity | 19.7% | 0.7% | 37.8% | — | — | — |
| Current ratio | 48.5% | 89.1% | 55.1% | 174.4% | 286.0% | 919.8% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Penetrium Bioscience / 페니트리움바이오 / 187660 / KRX:187660
Source: KRX statistical information